Bellevue Life Sciences Acquisition Corp risk profile
91 Acute at or past the historical limit
Measured 1 September 2026 from OSRH's filed statements. Recomputed nightly.
91 (Acute), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 80 | Acute | Volatile | One-year price volatility — 183.9% |
| Operating pressure | 66 | Stretched | Stable | Costs outgrowing revenue — +57.8 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.04x |
| Leverage and coverage | 100 | Acute | Stable | Net debt to EBITDA |
| Competitive position | 100 | Acute | Stable | Operating-margin gap against peers — -432.5 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Bellevue Life Sciences Acquisition Corp